InVitae has launched a hereditary pancreatic cancer panel that covers 17 genes related to pancreatic cancer and the option of adding two genes related to hereditary pancreatitis. The test costs $1,500 in the US and has a turnaround time of three weeks.
Enzymatics has updated its Archer FusionPlex ALK, RET, ROS1 Panel to now include select point mutations in ALK and RET that confer resistance to crizotinib.
MolecularMD, in collaboration with OncoMed, is developing a Notch1 next-generation sequencing-based test. The Notch1 NGS Assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from OncoMed's anti-Notch1 antibody, OMP-52M51.